Claim Missing Document
Check
Articles

Found 3 Documents
Search
Journal : Riset Informasi Kesehatan

The activity testing of kesambi leaves (Scheichera oleosa) ethanol extract on white mice of the Balb/C strain induced by ovalbumin Pacheco, Mergita Angela; Sunarni, Titik; Purwidyaningrum, Ika
Riset Informasi Kesehatan Vol 13 No 2 (2024): Riset Informasi Kesehatan
Publisher : Sekolah Tinggi Ilmu Kesehatan Harapan Ibu Jambi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30644/rik.v13i2.902

Abstract

Background: Asthma is a chronic inflammatory disorder of the respiratory tract that involves many cells. The anti-inflammatory effect of kesambi leaves is due to the presence of secondary metabolites. Flavonoid compounds are known to have potential effects as anti-inflammatory and antioxidants Method: This research uses the maceration method with 96% ethanol solvent. The test animals used were 26 white mice of the Balb/C strain which were divided into 6 treatment groups (N), (K-), (K+), (P1), (P2), (P3). Treatments on day 7 and day 14 were sensitized using OVA i.p. Next, on days 21, 23 and 25, 1% OVA was inhaled. On days 26 to 39, treatment was given, namely kesambi leaf extract (P1), (P2), (P3). On day 40, histopathologically discontinued. Data analysis using SPSS. Results: The yield of kesambi leaf extract was 28.2%. Data were analyzed using the Mann- Whitney and Wilcoxon tests at T0, T1 and T2 to determine differences in eosinophil counts. The results of the analysis of the eosinophil count were 70.23. Meanwhile, mast cell data analysis uses Mann Whitney 52.57 µm. Analysis of bronchiolar epithelial thickness data 73.33 µm. Conclusion: The effective dose of kesambi leaf ethanol extract is 400 mg/kgBW which can provide anti-asthma effects on blood eosinophils, mast cells and bronchiolar epithelial thickness in white mice induced by ovalbumin Balb/C.
Pharmacy installation performance analysis of Blitar Hospital through a balanced scorecard approach with a SWOT analysis framework in 2023 Wahyuningtiyas, Triya; Purwidyaningrum, Ika; Wijayanti, Tri
Riset Informasi Kesehatan Vol 13 No 2 (2024): Riset Informasi Kesehatan
Publisher : Sekolah Tinggi Ilmu Kesehatan Harapan Ibu Jambi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30644/rik.v13i2.880

Abstract

Background: The development of Blitar Hospital results from collaborative deliberation that requires comprehensive planning, financial allocation, intellectual consideration, and a strategic approach to achieve optimal results. Method: This study aims to evaluate the performance of the Pharmacy Installation using the Balanced Scorecard approach with SWOT to determine the position of the Pharmacy Installation as a strategy preparation. This type of research is descriptive non-experimental. Data were obtained through in-depth interviews with the Head of the Pharmacy Installation, questionnaires to employees and patients, and direct observation. Qualitative and quantitative descriptive analysis was used. Results: The results showed that performance: 1) Financial perspective: ITOR 2022 (6 times), 2023 (7.7 times); GPM 2022 (26.50%), 2023 (30.61%); GROSS 2022 (61%), 2023 (23.82%). 2) Internal business process perspective: Drug availability rate 2022 (98.48%), 2023 (97.96%); dispensing time of concocted prescription (47.30 minutes), non-concocted prescription (31.54 minutes); Provision of drug information: delivered 100%, except side effects (2.63%), duration of use (4.28%), Storage method (0%). 3) Growth and learning perspective: Employee morale is high; SIM needs feature optimization; Employee training level (100%). 4) Customer perspective: Patients are satisfied with the pharmacy installation services; customer retention period I (52%), period II 2023 (37%); customer acquisition period I (48%), period II (65%). SWOT analysis shows that the Pharmacy Installation is in quadrant II with a diversification strategy. Conclusion: The performance of Pharmacy Installation Blitar Hospital is good and can be improved.
Cost analysis and utility index in congestive heart failure patients in Hospital Dr. Moewardi Surakarta: bahasa inggris Lering, Maria Nona Adriani; Andayani, Tri Murti; Purwidyaningrum, Ika
Riset Informasi Kesehatan Vol 13 No 1 (2024): Riset Informasi Kesehatan
Publisher : Sekolah Tinggi Ilmu Kesehatan Harapan Ibu Jambi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30644/rik.v13i1.841

Abstract

Background: Congestive heart failure is a progressive disease that causes a decreased quality of life, increases the need for medical expenses, and has a long treatment time. The purpose of this study is to analyze the cost of treatment and see the utility index in patients with congestive heart failure at RSUD Dr. Moewardi Surakarta. Method: The research method used a cross-sectional design, data were collected retrospectively from medical records, financial data, and pharmaceutical installations to see data on direct medical costs and utility data using the EQ-5D-5L questionnaire during March-May. The subjects of the study were 78 outpatient heart failure patients at RSUD Dr. Moewardi Surakarta with inclusion criteria, namely heart failure patients aged > 40 years and complete medical record data including age, sex, comorbidities, degree of severity, and drug therapy. Results: Data were analyzed using the Man Whitney U test and the Kruskal Walis H test. The results of this study showed direct medical costs, namely pharmacy (Rp. 2,837,328.00), service fees (Rp. 150,000.00), medical procedures (Rp. 89,717.95), and administrative fees (Rp. 10,000.00). Total direct medical costs Rp. 3,087,045.95. The results of the EQ-5D-5L questionnaire based on each dimension were 78.2% no problems with walking ability, 97.4% no problems with self-care, 59.0% no problems with activities, 34.6% little had problems with pain, and 57.7% had no problems with anxiety/depression. The utility index value is 0.803. Conclusion: The conclusion is that the average direct medical cost is Rp. 3,087,045.95 and the utility index value is 0.803.